In vivo CAR-T is moving fast, and so are the manufacturing challenges behind it. LNPs and viral vectors are both gaining ground as delivery platforms, but each comes with a distinct set of constraints that are already shaping which programs will scale and which will stall. This webinar gets into the practical realities that don't always make it into the headlines.
- What does it actually take to manufacture a targeted RNA-LNP that selectively reprograms T cells in vivo?
- How do viral vector programs hold up when analytical and process demands hit at scale?
- And what does it look like when early development assumptions meet manufacturing reality?
Lonza's experts overview case studies from both platforms, sharing how specific manufacturing challenges were approached and resolved, and what that means for programs at the design stage today. If your work touches in vivo therapeutic development, this session will give you a clearer picture of what manufacturing readiness actually looks like in practice.
